Table 1.
Patient Characteristics
| Characteristic | Not Lymphopenic | Lymphopenic |
|---|---|---|
| (n = 174) | (n = 201) | |
| Age, y, mean (SD) | 48.7 (12.6) | 56.2 (9.6) |
| Male sex | 116 (66.7) | 155 (77.1) |
| Race | ||
| White | 139 (79.9) | 178 (88.6) |
| Black | 11 (6.3) | 10 (5) |
| Hispanic | 21 (12.1) | 10 (5) |
| Asian | 3 (1.7) | 3 (1.5) |
| Body mass index, kg/m2, mean (SD) | 27.4 (5.5) | 27.9 (5.3) |
| Etiology of heart failure | ||
| Ischemic cardiomyopathy | 57 (32.8) | 89 (44.3) |
| Nonischemic cardiomyopathy | 118 (67.8) | 114 (56.7) |
| Giant cell myocarditis | 2 (1.1) | 5 (3.5) |
| Comorbidity | ||
| Diabetes | 49 (28.2) | 78 (38.8) |
| Chronic kidney disease | 37 (21.3) | 70 (34.8) |
| History of solid tumor | 9 (5.2) | 12 (6.0) |
| History of hematologic malignancy | 11 (6.3) | 10 (5.0) |
| History of autoimmune disease | 10 (5.7) | 9 (4.5) |
| CMV serostatus risk group | ||
| Low | 40 (23.0) | 51 (25.4) |
| Intermediate | 86 (49.4) | 87 (43.3) |
| High | 48 (27.6) | 63 (31.3) |
| White blood cell count, ×103 cells/µL | ||
| Baseline, mean (SD) | 8.4 (3.3) | 7.7 (2.5) |
| 1 mo posttransplant, mean (SD) | 8.0 (3.1) | 7.5 (3.3) |
| Absolute neutrophil count, ×103 cells/µLa | ||
| Baseline, mean (SD) | 5.6 (3.0) | 5.5 (2.1) |
| 1 mo posttransplant, mean (SD) | 5.8 (2.6) | 6.4 (2.9) |
| Baseline ALC, ×103 cells/µLa, mean (SD) | 1.7 (0.6) | 1.1 (0.5) |
| Estimated GFR, mL/min/1.73 m2 | ||
| Pretransplant GFR, median (25th, 75th percentile) | 78.9 (59.4, 94.9) | 63.1 (49.0, 80.0) |
| 1 mo posttransplant GFR, median (25th, 75th percentile) | 76.9 (52.1, 96.3) | 54.2 (40.6, 76.8) |
| Required RRT following transplant | 8 (4.6) | 30 (14.9) |
| Induction therapy | ||
| None | 163 (95.9) | 161 (81.7) |
| Antithymocyte globulin | 0 (0.0) | 7 (3.6) |
| Basiliximab | 5 (2.9) | 21 (10.7) |
| Rituximab | 0 (0.0) | 3 (1.5) |
| Muromonab | 2 (1.2) | 5 (2.5) |
| Maintenance immunosuppressionb | ||
| Mycophenolate | 129 (91.4) | 176 (88.0) |
| Tacrolimus | 131 (75.3) | 130 (65.0) |
| Azathioprine | 9 (5.2) | 15 (7.4) |
| Cyclosporine | 43 (24.7) | 65 (32) |
| Sirolimus/everolimus | 3 (2) | 7 (3) |
| Antimicrobial prophylaxis | ||
| CMV immunoglobulin | 62 (35.6) | 68 (33.8) |
| Valganciclovir or ganciclovir | 132 (75.9) | 147 (73.9) |
| Trimethoprim-sulfamethoxazole | 161 (92.5) | 166 (83.0) |
| Dapsone | 3 (1.7) | 12 (6.0) |
| Rejection | ||
| Within first month | 23 (13.2) | 19 (9.5) |
| Within first year | 49 (28.2) | 54 (26.9) |
| After 1 mo, before 1 y, and prior to and outcome event | 8 (4.6) | 11 (5.5) |
| Inpatient at 1 mo | 20 (11.5) | 57 (28.4) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ALC, absolute lymphocyte count; CMV, cytomegalovirus; GFR, glomerular filtration rate estimated based on Chronic Kidney Disease Epidemiology Collaboration formula using serum creatinine; RRT, renal replacement therapy; SD, standard deviation [23].
aThere were 40 patients for whom a baseline blood count differential was not available within 2 weeks prior to surgery.
bAll but 2 patients in the cohort were also on a steroid in addition to the agents listed.